When: Current price $261.77 near 52-week high with MACD bearish crossover and price 37% up Bollinger Band

Then: Do not add; risk/reward asymmetric to downside (~5% to $248 vs ~2.7% upside to $267)

HOLD. Trim position into strength at 265-270; do not ADD on weakness to 254-258 given leverage profile and asymmetric risk-reward.

• MACD bearish cross with histogram negative and widening, ATR compressing from August peak, price 37% up Bollinger Band toward upper band at 269 - setup for failed rally or unresolved breakout at 52-week highs
• 16.1x forward earnings multiple on $16.28 EPS estimate versus $3.55 TTM GAAP represents 4.6x earnings recovery needed; any Q3 shortfall could push multiple from 16.1x to 20x+ at elevated price levels
• Qulipta menstrual migraine is real catalyst but single-digit percentage revenue addition over multiple years for a $462 billion company - incremental contribution, not transformation
• 2.69% dividend yield versus 10-year Treasury above 5% creates 230 basis point shortfall; income-oriented buyers have direct frictionless Treasury alternative
• Political drug pricing risk is identifiable and real - Polymarket pricing 88% probability of Democratic House with MFN executive order pressure recurring
• Patent cliff 2029-2031 on Skyrizi and Rinvoq is single largest concentration risk; pipeline needs to produce multiple meaningful assets or severe multiple compression likely
• Asymmetric risk-reward at current levels: approximately 2.7% upside to resistance versus 5% downside to support from 262
• Entry at 235 with current price 262; trailing stop at 248-250 represents 14-12 dollar risk on position already up 27 from entry
• Negative book equity and $62 billion net debt profile argues against adding capital at extended levels despite low beta
• 14.5% premium to 200-day moving average reflects incremental good news already priced in

→ vs aggressive: MACD bearish cross described as 'pause button' is speculative interpretation; actual data shows histogram negative and widening with momentum, volatility, and band position all aligned at 52-week highs - not a continuation setup without confirmation

→ vs aggressive: Cheap multiple framing of 16.1x forward earnings ignores that $16.28 estimate requires 4.6x recovery from $3.55 TTM GAAP with execution risk on Skyrizi, Rinvoq, and Elahere; 'cheap' multiple on expected normalization can prove expensive

→ vs aggressive: Qulipta transformation claim overstated; single-digit percentage addition to total revenue over multiple years for $462B company is contribution, not transformation, and 'sequential pricing' argument cuts both ways if prior readouts already in price

→ vs aggressive: Englander accumulation as conviction signal misreads position sizing; doubling from small base is quant behavior, not conviction call, and one 13F filing is data point, not thesis

→ vs aggressive: Defensive rotation on rates logic ignores arithmetic: 2.69% yield versus 5% risk-free is 230 bps shortfall; 'textbook talking point' doesn't underwrite actual headwinds for income bid supporting premium multiple

→ vs aggressive: Patent cliff 'not far' dismissal ignores that markets price 24-36 month patent risk routinely; calling pipeline 'dynamic' to dismiss 2029-2031 cliff is cavalier when single asset instead of three means severe compression

→ vs aggressive: Trim 'leaving 5-7 dollars on table' framing is expected return maximization logic, not risk management; asymmetric risk-reward deterioration is the signal to harvest gains, not chase excitement

→ vs aggressive: Stop widening to 250 contradicts position-sizing framework assuming adding capital at these levels; with entry at 235, 12-14 point stop risk on 27 point gain is sensible trailing stop, not opportunity to add

→ vs aggressive: ADD 25% on weakness to 254-258 at 52-week highs with negative book equity and $62B net debt contradicts low-beta thesis; stability and predictability argument actually supports smaller, disciplined position, not adding at extended levels

HOLD with modifications: maintain existing position, no new capital above $252, add 10-15% on confirmed retest of $248-$252 with bullish reversal, trim 15-20% only on price-momentum divergence above $265, hold $248 stop, and consider self-funding collar hedge (sell $275-$280 call, buy $245-$250 put)

• Qulipta Phase 3 readout is being "too generously" framed for a $462 billion company; it's not a fresh re-rating event if commercial potential is already in consensus
• Englander doubling is "not a thesis signal" — systematic franchises rebalance based on model signals, not conviction
• $248 stop is correct: aligns with lower Bollinger Band, 50-SMA trajectory zone, and September 8 low ($248.78 held with 5.2% bounce in four sessions)
• Negative book value ($9B annual buyback history, intangible-heavy M&A) is an "accounting artifact" — $17.8B FCF and $19B operating cash flow indicate no solvency risk
• Patent cliff (2029-2031) is 36-60 months away, outside the 24-36 month market pricing window; not an imminent multiple compressor
• 230 basis point dividend yield gap vs 10-year Treasury is "overweighted" — ABBV beta is 0.28, marginal seller is momentum trader, not income buyer
• Trim recommendation at $265-$270 before Q3 earnings is wrong: clean print could send stock to $280
• Add zone is $248-$252 (lower Bollinger, 50-SMA trajectory, September 8 pivot low convergence), not $254-$258 as aggressive wants or $230-$240 as trader planned
• Trim should be contingent on momentum (RSI divergence, MACD failure), not price alone
• Collar hedge (sell $275-$280 call, buy $245-$250 put) is recommended given 52-week highs, Q3 earnings in 6 weeks, and drug pricing political risk

→ vs aggressive: Qulipta "first-in-class commercial unlock" framing is too generous for a $462B company; markets discount expected value, not discrete event sequences, so Phase 3 success likely already priced

→ vs aggressive: $250 stop recommendation "removes one of three support signals" from risk framework; $248 has three layers of technical confluence (lower Bollinger, 50-SMA, September 8 low)

→ vs aggressive: Englander doubling is not thesis conviction — systematic quant franchises rebalance on model signals; larger position creates exit risk, not incremental bids

→ vs conservative: Negative book value is "accounting artifact" of buyback history and M&A, not structural insolvency risk; wrong metric to cite given $17.8B FCF and $19B operating cash flow

→ vs conservative: Patent cliff (2029-2031) is 36-60 months out, outside conservative analyst's own 24-36 month pricing window; not imminent overhang compressing multiple today

→ vs conservative: 230bp dividend yield vs Treasury gap is "overweighted" as multiple compressor; beta of 0.28 means marginal seller is momentum trader, not income buyer rotating to bonds

→ vs conservative: Trim at $265-$270 before Q3 earnings is wrong call — "harvesting gains" discipline fails when company is about to confirm earnings normalization; trim only warranted above $275 with negative momentum divergence

→ vs conservative: Neither aggressive nor conservative analyst addressed event risk protection through Q3 earnings; collar hedge is the critical missing element in both plans